Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 10c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of $1.56, $0.10 worse than the analyst estimate of $1.66. Revenue for the quarter came in at $44.84 million versus the consensus estimate of $26.1 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM